ClinicalTrials.gg
CompletedNCT00839826ODiXaHipUpdated Dec 17, 2014

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

A Phase 2 interventional study of Rivaroxaban (BAY59-7939) and Enoxaparin in Thromboembolism and Prevention, sponsored by Bayer. Completed at 41 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-17.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
641
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing rivaroxaban in Thromboembolism — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thromboembolism.

Enrollment
7th of 17
641 · median 112
Started
2002
the only one that year
Phase 2
Only one
of the 17
Registered
2nd of 17
by date
Lead sponsor
8 of 17
Bayer

Among the 17 studies testing rivaroxaban in Thromboembolism, this one is the 7th largest by enrollment, is the only one that started in 2002, is the only one in phase 2, and was the 2nd registered.

Thromboembolism

288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.

Browse Thromboembolism studies →

Open to participants now

4 of the 17 studies testing rivaroxaban in Thromboembolism are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing rivaroxaban in Thromboembolism, or all of them as a file.
02

Study summary

Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied below the skin (subcutaneously). Additionally, there is a chance of developing a heparin-induced thrombocytopenia (decrease in platelets). Therefore, there is still a need for new agents which are safer and more efficient and which are easier to apply.The purpose of this study is to compare the safety and efficacy of BAY 59-7939 with the safety and efficacy of the licensed drug Enoxaparin. Enoxaparin, a so-called low molecular heparin, is approved and widely used in the area of thromboprophylaxis and will be given once daily subcutaneously.Another important purpose of the study is to find the optimal dose of BAY 59-7939 for thromboprophylaxis after hip replacement surgery. Therefore, there are several dose steps planned.

03

Conditions studied

  • Thromboembolism
  • Prevention

Browse trials for

Keywords

  • Prevention of Thromboembolism after total hip replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 18 years or above and female patients.
  • Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis).
  • Patients' written for participation after receiving detailed written and oral previous information to any study specific procedures.

Exclusion criteria

Exclusion Criteria:

  • DVT or PE within the previous 6 months prior to study entry.
  • Myocardial infarction (MI) or cerebrovascular attack (CVA), or ischaemic stroke within the last 6 months prior to study entry.
  • History of heparin-induced thrombocytopenia, allergy to heparins.
  • Intracerebral or intraocular bleeding within the last 6 months prior to study entry.
  • History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study.
  • History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug
  • Amputation of one leg.Related to current symptoms or findings
  • Heart insufficiency III-IV.
  • Congenital or acquired haemorrhagic diathesis (PT /aPTT not within normal limits).
  • Thrombocytopenia ( \< 50.000/µl).
  • Macroscopic haematuria.
  • Allergy to contrast media.
  • Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg).
  • Impaired liver function (transaminases > 2 x ).
  • Impaired renal function (serum creatinine > 1.5 x ULN).
  • Active malignant disease.
  • Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding.
  • Body weight \< 45 kg.
  • Drug- or alcohol abuse.
  • Related to current treatment

    • Therapy with oral anticoagulants (e.g. phenprocoumon, warfarin-sodium).
    • Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment
    • Treatment with heparins or Factor Xa Inhibitors other than study medication.
    • All other drugs influencing coagulation, (exception: NSAIDs with half life \< 17 hrs will be allowed).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
641 participants (actual)

Study arms

  • Active comparator
    Arm 2

    Drug: Enoxaparin

  • Experimental
    Arm 1

    Drug: Rivaroxaban (BAY59-7939)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is a composite endpoint of: - Any DVT (proximal and/or distal) and - Non fatal PE and - Death from all causes. The primary endpoint will be evaluated 5 - 9 days after surgery.

    Time frame: Assymptomatic DVT will be measured 5-9 days after surgery Symptomatc DVT , non-fatal PE and Death from all causes will be measured 41 days after surgery

Secondary outcomes

  1. Incidence of DVTs (total, proximal, distal)

    Time frame: will be evaluated 5 - 9 days after surgery.

  2. Incidence of symptomatic VTEs

    Time frame: 41 days after surgery

  3. The composite endpoint that results from the primary endpoint by using alternative definition of deaths (i.e. VTE related death)

    Time frame: 41 days after surgery

  4. Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug.

    Time frame: 41 days after surgery

07

Study locations

41 sites
  • Wiener Neustadt, Niederösterreich 2700, Austria
  • Linz, Oberösterreich 4010, Austria
  • Wien, 1220, Austria
  • Baudour, 7331, Belgium
  • Bruxelles, 1090, Belgium
  • Gent, 9000, Belgium
  • HUY, 4500, Belgium
  • Hellerup, 2900, Denmark
  • Herlev, 2730, Denmark
  • Hørsholm, DK-2970, Denmark
  • Silkeborg, 8600, Denmark
  • Amiens, 80030, France
  • Lille Cedex, 59037, France
  • Nancy, 54037, France
  • Rheinfelden, Baden-Württemberg 79618, Germany
  • Fürth, Bayern 90766, Germany
  • Garmisch-Partenkirchen, Bayern 82467, Germany
  • Frankfurt, Hessen 60528, Germany
  • Frankfurt, Hessen 65929, Germany
  • Dresden, Sachsen 01307, Germany
  • Berlin, 14165, Germany
  • Haifa, 31096, Israel
  • Tel Aviv, 64239, Israel
  • Tel Hashomer, 52621, Israel
  • Zerifin, 70300, Israel
  • Amersfoort, 3818 ES, Netherlands
  • Zwolle, 8025 AB, Netherlands
  • Notodden, NO-3675, Norway
  • Oslo, 0440, Norway
  • Rjukan, NO-3660, Norway
  • Bialystok, 15-276, Poland
  • Gdansk, 80-742, Poland
  • Krakow, 31-826, Poland
  • Lodz, 91-425, Poland
  • Lublin, 20-090, Poland
  • Lublin, 20-718, Poland
  • Warszawa, 00-909, Poland
  • Göteborg, 416 85, Sweden
  • Jönköping, 551 85, Sweden
  • Kungälv, 442 83, Sweden
  • London, Greater London SE5 9RS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2009
First posted
Feb 10, 2009
Start
Dec 2002
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00839826
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 10, 2009
Start date
Dec 2002
Primary completion
Nov 2003
Completion
Nov 2003
Last update
Dec 17, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion